TABLE 1.
Description and the AMSTAR2 scores of included studies.
| Study | Conditions | Studies included | Study duration (median, range) | Daily dose (median, range) | Outcomes | AMSTAR scores | Study quality |
|---|---|---|---|---|---|---|---|
| Kim and Kang, (2020) | Donepezil versus Placebo | 7 | 5–25w | 7.5 mg | 1.MMSE,2.ADAS-cog, 3.CIBIC-plus orCGIC | 10 | high |
| Guekht et al. (2017) | Actovegin versus Placebo | 9 | 52w | — | 1.ADAS-cog, 2 | 9 | high |
| Jin and Liu (2019) | Rivastigmine versus Placebo | 12 | 18–24w | 6 mg | 1.ADAS-Cog, 2.MMSE, 3.ADL, 4.CDR + CIBIC | 9 | high |
| Kwon (2019) | Antiplatelet agents versus Placebo | 2 | 12w | -- | 1.MMSE | 4 | low |
| Jin and Liu (2019) | Memantine versus Placebo | 12 | 26w | 20 mg | 1.ADAS-Cog, 2.MMSE, 3.ADL, 4.CIBIC-plus orCGIC | 9 | high |
| Tan et al. (2015) | EGB761 versus Placebo | 9 | 22–26w | 200 mg | 1.ADAS-cog, 2.CIBIC-plus orCGIC, 3.ADL | 9 | high |
| Jin and Liu (2019) | Galantamine versus Placebo | 12 | 24–52w | 24 mg | 1.ADAS-Cog, 2.MMSE, 3.ADL, 4.CDR + CIBIC | 9 | high |
| Lopez-Arrieta and Birks (2002) | Nimodipine versus Placebo | 12 | 12–24w | 135 mg | 1.ADAS-cog, 2.CIBIC-plus orCGIC, 3.ADL, 4.Ad | 9 | high |
| Fan et al. (2021) | NPB + Citicoline versus Placebo | 26 | 12–52w | 200 mg | 1.MMSE, 2.BI, 3.NIHSS, 4.MoCA | 9 | high |
| Yi et al. (2020) | Olacetam versus Placebo | 42 | 12w | -- | 1.MMSE, 2.ADL, 3.MoCA, 4.BI,5.Ad | 10 | high |
| Fan et al. (2021) | NBP versus Placebo | 26 | 12–52w | 200 mg | 1.MMSE, 2.BI, 3.NIHSS, 4.MoCA | 9 | high |
| Fan et al. (2021) | NBP + Donepezil versus Placebo | 26 | 12–52w | 200mg/5 mg | 1.MMSE, 2.BI, 3.NIHSS, 4.MoCA | 9 | high |
| Fan et al. (2021) | Nimodipine versus Placebo | 26 | 12–52w | 60 mg | 1.MMSE, 2.BI, 3.NIHSS, 4.MoCA | 9 | high |
| Alvarez-Sabín et al. (2013) | Citicoline versus Placebo | 6 | 12–52w | 1 g | 1.MMSE, 2.ADL, 3.MoCA | 6 | middle |
| Huahui and Hehua (2015) | Oxiracetam versus Placebo | 4 | 24w | 4.0 g | 1.MMSE, 2.ADL, 3.MoCA | 4 | low |
| Ming (2016) | Salvianolate | 19 | 12–24w | 150 mg | 1.NIHSS, 2.BI | 10 | high |
| Wei (2020) | TCM + western medicine versus Placebo | 8 | 12–24w | -- | 1.MMSE, 2.MoCA, 3.ADL, 4.BI, 5.NIHSS | 7 | high |
| You et al. (2019) | Oxygen versus Placebo | 25 | 12–16w | 120 min, qd | 1.MMSE, 2.ADL, 3.Ad | 9 | high |
| Szatmári and Whitehouse, (2009) | Vinpocetine versus Placebo | 3 | 24w | 30–60 mg | 1.NIHSS, 2.AE | 4 | low |
TCM, traditional chinese medicine; NBP, DL-3-n-Butylphthalide; Olacetam: Au/Polypropionic Acid Nanoparticles Loaded with Olacetam.